MCID: ERY017
MIFTS: 54

Erythema Elevatum Diutinum

Categories: Bone diseases, Cardiovascular diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Elevatum Diutinum

MalaCards integrated aliases for Erythema Elevatum Diutinum:

Name: Erythema Elevatum Diutinum 12 54 60 45 15 74

Characteristics:

Orphanet epidemiological data:

60
erythema elevatum diutinum
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060567
MeSH 45 C535509
SNOMED-CT 69 58872001
ICD10 34 L95.1
MESH via Orphanet 46 C535509
ICD10 via Orphanet 35 L95.1
UMLS via Orphanet 75 C0263398
Orphanet 60 ORPHA90000
UMLS 74 C0263398

Summaries for Erythema Elevatum Diutinum

NIH Rare Diseases : 54 Erythema elevatum diutinum is a rare type of chronic cutaneous vasculitis characterized by red, purple, brown or yellow papules, plaques (thick, red patches of skin), or nodules.These lesions are located mainly on the knees, elbows, hands, feet, face, genitals and buttocks. Although it is a chronic condition, most cases respond well to treatment with dapsone. The cause of this condition remains unknown. 

MalaCards based summary : Erythema Elevatum Diutinum is related to vasculitis and arthritis. An important gene associated with Erythema Elevatum Diutinum is PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Heparin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and b cells, and related phenotypes are arthralgia and skin rash

Disease Ontology : 12 A vasculitis characterised by red, purple, brown or yellow papules (raised spot), plaques, or nodules, found on the backs of the hands, other extensor surfaces overlying joints, and on the buttocks.

Wikipedia : 77 Erythema elevatum diutinum is a form of... more...

Related Diseases for Erythema Elevatum Diutinum

Diseases related to Erythema Elevatum Diutinum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 114)
# Related Disease Score Top Affiliating Genes
1 vasculitis 10.7
2 arthritis 10.6
3 pyoderma 10.6
4 rheumatoid arthritis 10.6
5 pyoderma gangrenosum 10.6
6 myelodysplastic syndrome 10.5
7 crohn's disease 10.4
8 dermatitis 10.4
9 alk+ histiocytosis 10.4 CD1A F13A1
10 keratitis, hereditary 10.4
11 celiac disease 1 10.4
12 dermatitis herpetiformis, familial 10.4
13 leukemia 10.4
14 lymphoma 10.4
15 sarcoma 10.4
16 scleritis 10.4
17 relapsing polychondritis 10.4
18 human immunodeficiency virus infectious disease 10.4
19 acquired immunodeficiency syndrome 10.4
20 dermatitis herpetiformis 10.4
21 lupus erythematosus 10.4
22 granuloma annulare 10.3 F13A1 TNFRSF1B
23 myofibroma 10.3 CD1A F13A1
24 acute necrotizing encephalitis 10.3 FOXP3 TBX21
25 multifocal motor neuropathy 10.3 CD1A CD1E
26 kaposiform hemangioendothelioma 10.3 CD34 PECAM1
27 cochlear disease 10.3 GATA3 TNFRSF1B
28 anal canal adenocarcinoma 10.2 FOXP3 TNFRSF1B
29 acroosteolysis 10.2
30 spondyloarthropathy 1 10.2
31 leukemia, chronic lymphocytic 2 10.2
32 hashimoto thyroiditis 10.2
33 kaposi sarcoma 10.2
34 leukemia, chronic lymphocytic 10.2
35 systemic lupus erythematosus 10.2
36 porphyria cutanea tarda 10.2
37 myasthenia gravis 10.2
38 sjogren syndrome 10.2
39 hypereosinophilic syndrome, idiopathic 10.2
40 neutrophilic dermatosis, acute febrile 10.2
41 leukemia, chronic myeloid 10.2
42 diabetes mellitus 10.2
43 hepatitis 10.2
44 hepatitis b 10.2
45 keloids 10.2
46 lymphedema 10.2
47 ulcerative colitis 10.2
48 cutaneous lupus erythematosus 10.2
49 erythema multiforme 10.2
50 fibroma 10.2

Graphical network of the top 20 diseases related to Erythema Elevatum Diutinum:



Diseases related to Erythema Elevatum Diutinum

Symptoms & Phenotypes for Erythema Elevatum Diutinum

Human phenotypes related to Erythema Elevatum Diutinum:

60 33 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002829
2 skin rash 60 33 hallmark (90%) Very frequent (99-80%) HP:0000988
3 vasculitis in the skin 60 33 hallmark (90%) Very frequent (99-80%) HP:0200029
4 abnormal blistering of the skin 60 33 frequent (33%) Frequent (79-30%) HP:0008066
5 skin vesicle 60 33 frequent (33%) Frequent (79-30%) HP:0200037
6 increased antibody level in blood 60 33 frequent (33%) Frequent (79-30%) HP:0010702
7 myalgia 60 33 occasional (7.5%) Occasional (29-5%) HP:0003326
8 skin nodule 60 33 occasional (7.5%) Occasional (29-5%) HP:0200036

GenomeRNAi Phenotypes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD1A CD1D CD34 CXCL8 F13A1 S100A9

MGI Mouse Phenotypes related to Erythema Elevatum Diutinum:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 CD1D CD34 CD68 F13A1 FOXP3 GATA3
2 immune system MP:0005387 9.61 CD1D CD34 CD68 FOXP3 GATA3 PECAM1
3 respiratory system MP:0005388 9.1 CD1D F13A1 FOXP3 PECAM1 TBX21 TNFRSF1B

Drugs & Therapeutics for Erythema Elevatum Diutinum

Drugs for Erythema Elevatum Diutinum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 274)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
2
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 143 6006
3
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
4
Budesonide Approved Phase 4 51333-22-3 5281004 63006
5
Canagliflozin Approved Phase 4 842133-18-0
6
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051
7
Insulin glargine Approved Phase 4 160337-95-1
8
Insulin glulisine Approved Phase 4 207748-29-6
9
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
10
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
11
tannic acid Approved Phase 4,Phase 3 1401-55-4
12
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
13
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
14
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
15
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
16
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
17
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
18
Goserelin Approved Phase 4 65807-02-5 5311128 47725
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
20 Hormones Phase 4,Phase 3,Phase 2
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
22 Hormone Antagonists Phase 4,Phase 3,Phase 2
23 Immunologic Factors Phase 4,Phase 3,Phase 2
24 calcium heparin Phase 4,Phase 3
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Dermatologic Agents Phase 4,Phase 3,Phase 2
29 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
31 Vitamin B Complex Phase 4,Phase 3,Phase 2
32 Vitamin B9 Phase 4,Phase 3,Phase 2
33 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
34 Antimetabolites Phase 4,Phase 3,Phase 2
35 Folate Phase 4,Phase 3,Phase 2
36 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
38 Autonomic Agents Phase 4,Phase 3,Phase 2
39 Adrenergic beta-2 Receptor Agonists Phase 4
40 glucocorticoids Phase 4,Phase 3,Phase 2
41 Budesonide, Formoterol Fumarate Drug Combination Phase 4
42 Bronchodilator Agents Phase 4,Phase 3
43 Adrenergic Agents Phase 4,Phase 3
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
45 Respiratory System Agents Phase 4,Phase 3
46 Adrenergic Agonists Phase 4,Phase 3
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
48 Anti-Asthmatic Agents Phase 4,Phase 3
49 Formoterol Fumarate Phase 4
50 Adrenergic beta-Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma Completed NCT02062463 Phase 4 Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX;SYMBICORT TURBOHALER budesonide and formoterol fumarate
2 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Completed NCT02752776 Phase 4 Secukinumab
3 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus Completed NCT01989754 Phase 4 Placebo;Canagliflozin, 100 mg;Canagliflozin, 300 mg
4 Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed NCT00965549 Phase 4 INSULIN GLARGINE (HOE901);Insulin aspart;Insulin Glulisine
5 Local Phase 4 Pan-European SMART Study Completed NCT00463866 Phase 4 Budesonide/formoterol
6 AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers Completed NCT01084577 Phase 4
7 Stopping Aminosalicylate Therapy in Inactive Crohn's Disease Recruiting NCT03261206 Phase 4
8 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life Recruiting NCT03774875 Phase 4 Apremilast (CC-10004);Apremilast (CC-10004)
9 A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study) Recruiting NCT02616666 Phase 4 Dapagliflozin;Standard of Care
10 A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage Terminated NCT01661140 Phase 4 Methotrexate (stable dose);Tocilizumab;Methotrexate (tapering dose)
11 GP Extended Action Triptorelin Terminated NCT01673984 Phase 4 Decapeptyl® SR 22.5mg;Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
12 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
13 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
14 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
15 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed NCT00412984 Phase 3 warfarin;apixaban
16 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease Completed NCT00501059 Phase 3 Aspirin (Acetylsalicylic acid, BAYE4465);Placebo
17 Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain Completed NCT01337089 Phase 3 Nabiximols
18 Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer Completed NCT01262651 Phase 3 Nabiximols;Placebo (GA-0034)
19 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
20 A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
21 A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Completed NCT02046603 Phase 3 Tocilizumab;DMARDs;Oral Corticosteroids;Methotrexate
22 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension Completed NCT01788358 Phase 3 Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
23 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed NCT01764633 Phase 3 Placebo
24 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed NCT01336023 Phase 3 insulin degludec/liraglutide;insulin degludec;liraglutide
25 Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT01313676 Phase 3 fluticasone furoate/vilanterol;fluticasone furoate;vilanterol
26 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Completed NCT01424566 Phase 3 Nabiximols;Placebo (GA-0034)
27 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3 tocilizumab [RoActemra/Actemra]
28 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. Completed NCT00750880 Phase 3 tocilizumab [RoActemra/Actemra]
29 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
30 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed NCT00660907 Phase 3 dapagliflozin;glipizide;metformin hydrochloride
31 A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain Completed NCT01439100 Phase 3 Oxycodone/Naloxone Prolonged Release tablets;Placebo
32 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed NCT00602472 Phase 3 linagliptin;placebo
33 Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00400153 Phase 3 Atrovent Respimat (20 mcg);COMBIVENT MDI (36/206 mcg);Combivent Respimat (20 mcg/100 mcg);Placebo via corresponding inhaler for blinding purposes
34 Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes Completed NCT00184600 Phase 3 biphasic insulin aspart;insulin detemir;insulin aspart
35 Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) Completed NCT00479661 Phase 3 Dexmedetomidine;Propofol
36 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
37 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed NCT00069121 Phase 3 capecitabine [Xeloda];Oxaliplatin;Oxaliplatin;Leucovorin;5 FU
38 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed NCT00633893 Phase 3 Apixaban;Placebo
39 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
40 A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) Recruiting NCT03283085 Phase 3 25 mg SHP647;75 mg SHP647
41 Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Recruiting NCT03259334 Phase 3 SHP647
42 Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours Recruiting NCT02804815 Phase 3 Aspirin 100mg;Aspirin 300mg;Placebo 100mg;Placebo 300mg
43 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Recruiting NCT03524092 Phase 3 Mirikizumab;Mirikizumab;Placebo
44 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Recruiting NCT03518086 Phase 3 Mirikizumab;Placebo
45 Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year Recruiting NCT03464136 Phase 3
46 A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Recruiting NCT03105128 Phase 3 placebo for risankizumab;risankizumab IV;risankizumab SC
47 A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989 Recruiting NCT03105102 Phase 3 placebo for risankizumab SC;risankizumab IV;placebo for risankizumab IV;risankizumab SC
48 A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment Recruiting NCT03104413 Phase 3 placebo for risankizumab IV;risankizumab SC;risankizumab IV
49 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Recruiting NCT02914561 Phase 3 Filgotinib;Placebo to match filgotinib
50 A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Recruiting NCT02615873 Phase 3 Accordion Pill™ Carbidopa/Levodopa

Search NIH Clinical Center for Erythema Elevatum Diutinum

Cochrane evidence based reviews: erythema elevatum diutinum

Genetic Tests for Erythema Elevatum Diutinum

Anatomical Context for Erythema Elevatum Diutinum

MalaCards organs/tissues related to Erythema Elevatum Diutinum:

42
Skin, Breast, B Cells, Neutrophil, Liver, Bone, Prostate

Publications for Erythema Elevatum Diutinum

Articles related to Erythema Elevatum Diutinum:

(show top 50) (show all 209)
# Title Authors Year
1
Erythema elevatum diutinum: a case report and review of literature. ( 30074624 )
2019
2
Erythema elevatum diutinum a rare and poorly understood cutaneous vasculitis: A single institution experience. ( 30362150 )
2019
3
Late-stage nodular erythema elevatum diutinum mimicking sclerotic fibroma. ( 29068068 )
2018
4
Erythema elevatum diutinum with pustule formation: An unusual finding. ( 29292528 )
2018
5
Late-Stage Erythema Elevatum Diutinum Mimicking a Fibroblastic Tumor: A Potential Pitfall. ( 29293121 )
2018
6
Erythema elevatum diutinum-like vasculitis secondary to cocaine adulterated with levamisole. ( 29423942 )
2018
7
Erythema Elevatum Diutinum Treated With Mycophenolate Mofetil. ( 29509562 )
2018
8
Erythema elevatum diutinum verbunden mit schwerer oropharyngealer Ulzeration und Pyoderma gangraenosum. ( 29750450 )
2018
9
Erythema elevatum diutinum associated with severe oropharyngeal ulceration and pyoderma gangrenosum. ( 29750453 )
2018
10
Pyoderma gangrenosum and erythema elevatum diutinum associated with a high-risk myelodysplastic syndrome: case report. ( 30057994 )
2018
11
Unusual presentation of erythema elevatum diutinum with underlying hepatitis B infection. ( 30063775 )
2018
12
Erythema elevatum diutinum. ( 30066783 )
2018
13
HIV-associated erythema elevatum diutinum: a case report and review of a clinically distinct variant. ( 30142732 )
2018
14
Rare presentation of erythema elevatum diutinum. ( 30238047 )
2018
15
Primary Surgical Treatment of Erythema Elevatum Diutinum. ( 30241974 )
2018
16
Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. ( 28917218 )
2017
17
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. ( 27930381 )
2017
18
A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. ( 28050587 )
2017
19
Erythema Elevatum Diutinum. ( 28183422 )
2017
20
Erythema elevatum diutinum in a healthy child. ( 28397292 )
2017
21
Erythema elevatum diutinum-associated with loss of the uvula. ( 28443312 )
2017
22
Erythema elevatum diutinum involving palms and soles: a case report and literature review. ( 28469800 )
2017
23
Erythema elevatum diutinum presenting with palmoplantar keratoderma. ( 28512994 )
2017
24
Vesiculobullous variant of erythema elevatum diutinum. ( 28639709 )
2017
25
Complete resolution of erythema elevatum diutinum using oral sulfasalazine. ( 29469798 )
2017
26
Truncal Erythema Elevatum Diutinum With Elevated Cryoglobulin Level. ( 29901001 )
2017
27
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
28
Granuloma Faciale and Erythema Elevatum Diutinum in Relation to Immunoglobulin G4-Related Disease: An Appraisal of 32 Cases. ( 27124923 )
2016
29
Erythema elevatum diutinum in acquired immune deficiency syndrome: Can it be an immune reconstitution inflammatory syndrome? ( 27190420 )
2016
30
Erythema elevatum diutinum in association with IgA monoclonal gammopathy: A rare case report. ( 27559509 )
2016
31
Case of erythema elevatum diutinum associated with IgA paraproteinemia successfully controlled with thalidomide and plasma exchange. ( 25257541 )
2015
32
Erythema elevatum diutinum: an atypical presentation. ( 25521326 )
2015
33
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia. ( 25754401 )
2015
34
Erythema elevatum diutinum and hypothyroidism: coincidence or causal relationship? ( 26375227 )
2015
35
A Case of Erythema Elevatum Diutinum With Pancytopenia: Focus on Dapsone-Induced Hematologic Side Effects and Colchicine as a Safe Treatment Option. ( 26461818 )
2015
36
Erythema elevatum diutinum coexisting with ankylosing spondylitis. ( 27708930 )
2015
37
Erythema elevatum diutinum in association with dermatitis herpetiformis. ( 24616856 )
2014
38
Erythema elevatum diutinum. ( 23487831 )
2014
39
An unusual case of erythema elevatum diutinum with penile and laryngeal manifestations. ( 24413401 )
2014
40
An atypical distribution of erythema elevatum diutinum. ( 24479627 )
2014
41
An unusual case of Sweet syndrome in a child: overlapping presentation with erythema elevatum diutinum. ( 24521734 )
2014
42
Erythema elevatum diutinum (EED): a distinctive vasculitis with acute-on-chronic features. ( 24652434 )
2014
43
Erythema elevatum diutinum: a review of presentation and treatment. ( 25288365 )
2014
44
Nodular Erythema Elevatum Diutinum Mimicking Kaposi's Sarcoma in a Human Immunodeficiency Virus Infected Patient. ( 25484391 )
2014
45
Atypical erythema elevatum diutinum or extrafacial granuloma faciale? ( 23253514 )
2013
46
Erythema elevatum diutinum. ( 23442466 )
2013
47
Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. ( 23652900 )
2013
48
Erythema elevatum diutinum: a new vesiculobullous case. ( 24001509 )
2013
49
Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease. ( 24073904 )
2013
50
Successful combination therapy with dapsone and cyclosporine for erythema elevatum diutinum with unusual appearance. ( 22132683 )
2012

Variations for Erythema Elevatum Diutinum

Expression for Erythema Elevatum Diutinum

Search GEO for disease gene expression data for Erythema Elevatum Diutinum.

Pathways for Erythema Elevatum Diutinum

GO Terms for Erythema Elevatum Diutinum

Cellular components related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.65 CD1B CD1C CD1D CD1E CD34
2 endosome GO:0005768 9.43 CD1A CD1B CD1C CD1D CD1E CD68
3 cell surface GO:0009986 9.33 CD1B CD1D CD34
4 endosome membrane GO:0010008 9.02 CD1A CD1B CD1C CD1D CD68
5 plasma membrane GO:0005886 10.02 CD1A CD1B CD1C CD1D CD1E CD34

Biological processes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.91 CD1A CD1B CD1C CD1D CD1E GATA3
2 neutrophil degranulation GO:0043312 9.88 CD68 PECAM1 S100A9 TNFRSF1B
3 immune response GO:0006955 9.87 CD1A CD1B CD1C CD1D CD1E CXCL8
4 positive regulation of gene expression GO:0010628 9.86 CD34 FOXP3 GATA3 TBX21
5 adaptive immune response GO:0002250 9.81 CD1A CD1B CD1C CD1E
6 cytokine-mediated signaling pathway GO:0019221 9.8 CXCL8 F13A1 GATA3 TNFRSF1B
7 regulation of immune response GO:0050776 9.73 CD1A CD1B CD1C CD1D CD34 TBX21
8 response to virus GO:0009615 9.71 FOXP3 GATA3 TBX21
9 negative regulation of inflammatory response GO:0050728 9.7 FOXP3 GATA3 TNFRSF1B
10 cytokine production GO:0001816 9.58 FOXP3 S100A9
11 negative regulation of interleukin-2 production GO:0032703 9.58 FOXP3 GATA3 TBX21
12 negative regulation of interferon-gamma production GO:0032689 9.57 FOXP3 GATA3
13 positive regulation of interleukin-4 production GO:0032753 9.55 FOXP3 GATA3
14 positive regulation of T cell mediated cytotoxicity GO:0001916 9.55 CD1A CD1B CD1C CD1D CD1E
15 negative regulation of T-helper 17 cell differentiation GO:2000320 9.48 FOXP3 TBX21
16 lymphocyte migration GO:0072676 9.46 GATA3 TBX21
17 glomerular endothelium development GO:0072011 9.43 CD34 PECAM1
18 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.35 CD1A CD1B CD1C CD1D CD1E
19 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.02 CD1A CD1B CD1C CD1D CD1E

Molecular functions related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopeptide binding GO:0071723 9.55 CD1A CD1B CD1C CD1D CD1E
2 endogenous lipid antigen binding GO:0030883 9.35 CD1A CD1B CD1C CD1D CD1E
3 exogenous lipid antigen binding GO:0030884 9.02 CD1A CD1B CD1C CD1D CD1E

Sources for Erythema Elevatum Diutinum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....